Holen Sie sich die Stockscreener-App
3.10
5.44%
0.16
Handel nachbörslich:
3.00
-0.10
-3.23%
Schlusskurs vom Vortag:
$2.94
Offen:
$2.91
24-Stunden-Volumen:
2.77M
Relative Volume:
1.46
Marktkapitalisierung:
$333.00M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-2.562
EPS:
-1.21
Netto-Cashflow:
$-120.82M
1W Leistung:
+1.31%
1M Leistung:
-24.02%
6M Leistung:
-67.54%
1J Leistung:
-68.50%
1-Tages-Spanne:
$2.80
$3.13
1-Wochen-Bereich:
$2.715
$3.29
52-Wochen-Spanne:
$2.70
$13.01
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
3.10 | 333.00M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $580,000 Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
The Manufacturers Life Insurance Company Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com India
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa
TNGX Stock Hits 52-Week Low at $2.7 Amid Market Challenges - Investing.com UK
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Tango Therapeutics (NASDAQ:TNGX) - Defense World
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Unveiling 5 Analyst Insights On Tango Therapeutics - Benzinga
Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth? - Simply Wall St
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Tango Therapeutics Issues 218,750 Shares in Employee Equity Compensation Package - StockTitan
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 21.7% - MarketBeat
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock By Investing.com - Investing.com Canada
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com
Trv Gp Iv LLC Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World
B. Riley Forecasts Higher Earnings for Tango Therapeutics - MarketBeat
B. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00 - Defense World
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 inhibitor progress - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Earns “Buy” Rating from HC Wainwright - Defense World
The Analyst Landscape: 5 Takes On Tango Therapeutics - Benzinga
B. Riley Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
FY2024 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for TNGX - MarketBeat
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock - Investing.com India
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock By Investing.com - Investing.com Australia
Tango Therapeutics' (TNGX) Buy Rating Reiterated at HC Wainwright - MarketBeat
EcoR1 Capital, LLC Adjusts Stake in Tango Therapeutics Inc - GuruFocus.com
Wedbush Has Pessimistic Outlook of TNGX FY2024 Earnings - Defense World
Wedbush Forecasts Reduced Earnings for Tango Therapeutics - MarketBeat
Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Tango Therapeutics sees $9.67m stock sale by Boxer Capital - Investing.com Nigeria
Tango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at Guggenheim - MarketBeat
Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks
Two to Tango: Brain cancer drugs go further into development - BioWorld Online
Tango stock plunges 28% amid pipeline updates, Q3 earnings report - MSN
Tango stock plunges 28% amid pipeline updates, Q3 earnings report (NASDAQ:TNGX) - Seeking Alpha
U.S. Stock market: Sunnova energy(-42.35%0, Zoomcar(-38.48%), Tango therapeutics(-27.22%) among stock losers during early trading - Business Upturn
Tango Shares Plunge After 3Q Loss, Product Plans - MarketWatch
Tango Therapeutics advances cancer drug into full development By Investing.com - Investing.com Canada
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - BioSpace
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tango Therapeutics advances cancer drug into full development - Investing.com
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tango Therapeutics Inc-Aktie (TNGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rothenberg Mace | Director |
Nov 14 '24 |
Buy |
3.62 |
10,000 |
36,200 |
21,250 |
| EcoR1 Capital, LLC | 10% Owner |
Nov 06 '24 |
Sale |
3.28 |
1,494,558 |
4,896,023 |
11,836,178 |
| EcoR1 Capital, LLC | 10% Owner |
Nov 07 '24 |
Sale |
2.94 |
1,205,442 |
3,539,720 |
10,630,736 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):